Market Closed -
Nasdaq
21:30:01 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
4.45
USD
|
-0.67%
|
|
+6.97%
|
-25.71%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
531.5
|
1,315
|
2,492
|
2,140
|
1,227
|
918.2
|
-
|
-
|
Enterprise Value (EV)
1 |
479.9
|
1,198
|
2,124
|
2,140
|
1,654
|
1,152
|
1,177
|
1,009
|
P/E ratio
|
-3.67
x
|
-6.83
x
|
-13.4
x
|
-8.63
x
|
-5.08
x
|
-7.06
x
|
-12.9
x
|
15.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
10.9
x
|
73.8
x
|
15.9
x
|
7.9
x
|
3.7
x
|
2.32
x
|
1.9
x
|
1.58
x
|
EV / Revenue
|
9.83
x
|
67.3
x
|
13.5
x
|
7.9
x
|
4.99
x
|
2.92
x
|
2.43
x
|
1.74
x
|
EV / EBITDA
|
-4.86
x
|
-6.88
x
|
-12
x
|
-14.6
x
|
-16.2
x
|
-20.6
x
|
180
x
|
-
|
EV / FCF
|
-5.34
x
|
-7.28
x
|
-14.7
x
|
-13.1
x
|
-17
x
|
52.9
x
|
12.1
x
|
6.15
x
|
FCF Yield
|
-18.7%
|
-13.7%
|
-6.81%
|
-7.63%
|
-5.88%
|
1.89%
|
8.26%
|
16.3%
|
Price to Book
|
10.4
x
|
-68.5
x
|
-23.9
x
|
-7.32
x
|
-2.71
x
|
-1.85
x
|
-1.75
x
|
-1.81
x
|
Nbr of stocks (in thousands)
|
154,059
|
176,566
|
179,936
|
186,424
|
204,809
|
206,331
|
-
|
-
|
Reference price
2 |
3.450
|
7.450
|
13.85
|
11.48
|
5.990
|
4.450
|
4.450
|
4.450
|
Announcement Date
|
05/03/20
|
25/02/21
|
23/02/22
|
21/02/23
|
26/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
48.84
|
17.81
|
157.2
|
270.8
|
331.4
|
395.1
|
484.4
|
580.7
|
EBITDA
1 |
-98.73
|
-174
|
-176.9
|
-147
|
-102.1
|
-56
|
6.52
|
-
|
EBIT
1 |
-99.46
|
-174.8
|
-177.7
|
-148.4
|
-103.7
|
-43.92
|
28.12
|
118.3
|
Operating Margin
|
-203.66%
|
-981.12%
|
-113.08%
|
-54.81%
|
-31.29%
|
-11.12%
|
5.8%
|
20.38%
|
Earnings before Tax (EBT)
1 |
-108.9
|
-182.8
|
-181.8
|
-244.4
|
-226.2
|
-137.5
|
-65.76
|
66.33
|
Net income
1 |
-108.9
|
-182.8
|
-184.1
|
-247.1
|
-226.5
|
-128.4
|
-65.76
|
61.23
|
Net margin
|
-222.99%
|
-1,026.35%
|
-117.11%
|
-91.25%
|
-68.36%
|
-32.49%
|
-13.58%
|
10.54%
|
EPS
2 |
-0.9400
|
-1.090
|
-1.030
|
-1.330
|
-1.180
|
-0.6304
|
-0.3455
|
0.2860
|
Free Cash Flow
1 |
-89.93
|
-164.6
|
-144.5
|
-163.2
|
-97.31
|
21.78
|
97.21
|
164
|
FCF margin
|
-184.14%
|
-924.12%
|
-91.97%
|
-60.26%
|
-29.36%
|
5.51%
|
20.07%
|
28.25%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
1,490.8%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
267.87%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/03/20
|
25/02/21
|
23/02/22
|
21/02/23
|
26/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
40.99
|
47.16
|
49.92
|
65.53
|
75.83
|
79.54
|
68.78
|
82.49
|
86.74
|
93.4
|
85.51
|
98.28
|
103
|
108.5
|
105
|
EBITDA
|
-44.36
|
-52.01
|
-49.64
|
-34.39
|
-17.06
|
-45.92
|
-28.01
|
-
|
-
|
-42.25
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-44.58
|
-52.18
|
-49.96
|
-34.72
|
-17.44
|
-46.31
|
-28.42
|
-20.7
|
-11.92
|
-42.67
|
-22.63
|
-9.967
|
-6.217
|
-4.774
|
-1.937
|
Operating Margin
|
-108.76%
|
-110.64%
|
-100.07%
|
-52.98%
|
-23.01%
|
-58.22%
|
-41.31%
|
-25.1%
|
-13.74%
|
-45.68%
|
-26.47%
|
-10.14%
|
-6.04%
|
-4.4%
|
-1.84%
|
Earnings before Tax (EBT)
1 |
-58.8
|
-15.53
|
-73.92
|
-58
|
-41
|
-71.47
|
-52.66
|
-74.59
|
-35.82
|
-63.16
|
-44.64
|
-32.41
|
-29.23
|
-28.54
|
-19.66
|
Net income
1 |
-58.8
|
-17.78
|
-74.2
|
-58.86
|
-42.52
|
-71.54
|
-53.33
|
-75.33
|
-36.15
|
-61.73
|
-42.57
|
-29.97
|
-26.42
|
-25.93
|
-19.66
|
Net margin
|
-143.44%
|
-37.7%
|
-148.62%
|
-89.82%
|
-56.08%
|
-89.94%
|
-77.54%
|
-91.31%
|
-41.67%
|
-66.09%
|
-49.79%
|
-30.49%
|
-25.66%
|
-23.89%
|
-18.72%
|
EPS
2 |
-0.3300
|
-0.1000
|
-0.4000
|
-0.3200
|
-0.2300
|
-0.3800
|
-0.2800
|
-0.4000
|
-0.1900
|
-0.3100
|
-0.2107
|
-0.1510
|
-0.1290
|
-0.1241
|
-0.0900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/11/21
|
23/02/22
|
05/05/22
|
04/08/22
|
01/11/22
|
21/02/23
|
03/05/23
|
03/08/23
|
02/11/23
|
26/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
427
|
234
|
259
|
91.1
|
Net Cash position
1 |
51.6
|
117
|
368
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-4.181
x
|
-4.179
x
|
39.68
x
|
-
|
Free Cash Flow
1 |
-89.9
|
-165
|
-145
|
-163
|
-97.3
|
21.8
|
97.2
|
164
|
ROE (net income / shareholders' equity)
|
-249%
|
-1,925%
|
-
|
-
|
-
|
-34.9%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-67.6%
|
-71.7%
|
-52%
|
-
|
-42.5%
|
-32.1%
|
-25.2%
|
-15.5%
|
Assets
1 |
161.1
|
255
|
354
|
-
|
533.5
|
399.5
|
260.8
|
-395.7
|
Book Value Per Share
2 |
0.3300
|
-0.1100
|
-0.5800
|
-1.570
|
-2.210
|
-2.400
|
-2.540
|
-2.460
|
Cash Flow per Share
2 |
-0.7800
|
-0.8200
|
-0.7900
|
-0.8700
|
-0.5000
|
-0.4400
|
-0.1200
|
-
|
Capex
1 |
0.34
|
0.51
|
2.39
|
1.35
|
2.17
|
0.36
|
0.18
|
0.37
|
Capex / Sales
|
0.7%
|
2.89%
|
1.52%
|
0.5%
|
0.65%
|
0.09%
|
0.04%
|
0.06%
|
Announcement Date
|
05/03/20
|
25/02/21
|
23/02/22
|
21/02/23
|
26/02/24
|
-
|
-
|
-
|
Last Close Price
4.45
USD Average target price
12.2
USD Spread / Average Target +174.16% Consensus |
1st Jan change
|
Capi.
|
---|
| -25.71% | 918M | | -1.43% | 104B | | +8.96% | 105B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|